Format

Send to

Choose Destination
Australas J Dermatol. 2018 Feb;59(1):10-25. doi: 10.1111/ajd.12646. Epub 2017 Aug 17.

Atypical fibroxanthoma management: Recurrence, metastasis and disease-specific death.

Author information

1
Skin and Cancer Foundation, Sydney, New South Wales, Australia.
2
Department of Medicine, University of Queensland, Brisbane, Queensland, Australia.
3
Department of Dermatology, University of Sydney, Sydney, New South Wales, Australia.

Abstract

Atypical fibroxanthoma (AFX) is a rare spindle cell neoplasm predominantly found on the head and neck of elderly individuals with sun-damaged skin, with no evidence-based guidelines for their management. A systematic retrospective review of the literature focusing on treatment modality found a recurrence and metastasis rate of 8.0% (5.6% when adjusted for incomplete excisions) and 0.5% for local excision and 4.6% and 3.2% for Mohs micrographic surgery, respectively. Our results suggest that with clear surgical margins, AFX is unlikely to recur and metastases are rare, with significantly higher rates in the immunosuppressed population.

KEYWORDS:

AFX ; AFX management; AFX treatment; atypical fibroxanthoma; review

PMID:
28815551
DOI:
10.1111/ajd.12646
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center